Hints and tips:
...Janssen is the pharmaceutical division of J&J....
...Not only was the BioNTech/Pfizer vaccine the first to be deployed but it has suffered less from rare side effects and manufacturing glitches than its big western rivals Oxford/AstraZeneca, Janssen or Moderna...
...A booster shot of Johnson & Johnson’s Covid-19 vaccine produced a strong and rapid antibody response against the virus, the pharmaceutical company said on Wednesday....
...“The Janssen vaccine will be another weapon in our arsenal to beat this pandemic,” said vaccines minister Nadhim Zahawi....
FDA will now weigh whether to allow use of first single-dose jab to prevent the virus
..., J&J’s pharmaceutical division, told the panel on Friday: “Janssen’s vaccine candidate would play a critical role in the global efforts to fight Covid-19 . . ....
...“At present, no clear causal relationship has been established between these rare events and the Janssen [J&J] Covid-19 vaccine,” it said, adding that it was working closely with experts and regulators to...
...J&J is preparing to test a new formulation that could be targeted at the 501.v2 variant, but Mathai Mammen, global head of research and development for Janssen, J&J’s pharmaceuticals division, said he was...
...“The acquisition was driven by the significant opportunity seen in nipocalimab, along with the scientific capability Janssen is acquiring with the Momenta team,” J&J said in a statement....
...Through its Janssen subsidiary, the New Jersey-based drugmaker will administer its experimental vaccine to 6,000 UK volunteers in two doses in a phase-3 trial....
...He joined Janssen, J&J’s pharma division, in sales in 1988, with only a BA in biology....
...J&J — best known for consumer products such as “no more tears” baby shampoo — owns the Janssen pharmaceuticals business that sold two prescription opioids....
...Allergan, a Dublin-based pharmaceuticals company, is developing another antidepressant based on the glutamate system. It hopes to announce the results of its phase-3 clinical study on Rapastinel soon....
...Mr Rouse acknowledges that, Janssen’s enthusiasm aside, other companies have been less convinced of the advantages of outcomes-based pricing....
...Two leading pharmaceutical companies have warned that the UK must continue to attract top scientific talent if it is to maintain its competitive edge....
...In a statement on Wednesday, Scott White, president at Janssen Biotech, a pharmaceuticals unit of J&J, said: “We are effectively competing on value and price and to date, Pfizer has failed to demonstrate...
...Ms Foa added: “Pharmaceutical companies are clear that their drugs are for saving the lives of patients, not ending the lives of prisoners....
...Johan Van Hoof, head of infectious diseases and vaccines at Janssen, part of the Johnson & Johnson pharmaceuticals group, says he also has cause for optimism....
...One team is a collaboration between the Scripps Research Institute in California and the Janssen Prevention Centre in the Netherlands, part of the Johnson and Johnson pharmaceutical group; the other is at...
...Shares of Isis Pharmaceuticals gained nearly 11 per cent to $69.19, after the company announced a collaboration with Janssen Biotech, a subsidiary of Johnson & Johnson, to develop drugs to treat autoimmune...
...The grants available depend on the size of the investment, which has to be in one of six priority sectors: logistics, pharmaceuticals/life sciences, aerospace/aeronautics, agrifood, mechanical engineering...
...Average R&D intensity — the percentage of revenue invested in R&D — among drugmakers is almost 15 per cent, according to research by Deloitte, commissioned by Janssen, the pharmaceuticals arm of Johnson...
...Bill Hait, global head of research and development for Janssen, the pharmaceuticals arm of Johnson & Johnson, says the combination of big data and advances in genomic science is greatly increasing the potential...
...Addressing that issue is at the heart of Phil Dahlin’s role as director of sustainability for Janssen, the pharmaceuticals arm of Johnson & Johnson, the US consumer goods group....
...A step forward came from 2011 with the new so-called protease inhibitors from Merck, Vertex Pharmaceuticals and, more recently, Janssen, part of Johnson & Johnson....
International Edition